Co-Diagnostics Strengthens IP Portfolio with New International CoPrimer™ Patent

July 22, 2021

Co-Diagnostics has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea’s Intellectual Property Office for the Company’s CoPrimer™ technology.

Developed in 2013, Co-Diagnostics’ solely-owned CoPrimer technology received its first patent from the US Patent Office in 2018, and underpins the company’s molecular diagnostic test products that have been used in laboratories and hospitals in over 50 countries and across the US.

“We believe that this patent granted by South Korea provides additional validation of the uniqueness and versatility of the CoPrimer platform,” said Dwight Egan, Chief Executive Officer of Co-Diagnostics.

Among the numerous molecular diagnostic products using CoPrimer technology to have received regulatory clearance is the Logix Smart™ COVID-19 Test kit, of which the Company has sold millions since the pandemic began and which the Company had previously announced is effective in detecting all known strains and variants of SARS-CoV-2, including the Delta variant.

Co-Diagnostics’ business model of selling tests to US CLIA labs and their international equivalents continues to drive strong sales. Its COVID-19 test kit has been authorized for use as an in vitro diagnostic (IVD) by regulatory authorities in the US, the European Community, Mexico, India, Australia, and others.